E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Infantile spasms is a rare and severe epilepsy condition in which children experience a specific type of seizure (spasm) along with abnormal brain activity |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021750 |
E.1.2 | Term | Infantile spasms |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part A: - Evaluate the safety and tolerability of radiprodil in subjects with drug-resistant infantile spasms - Evaluate the pharmacokinetics of radiprodil in subjects with drug-resistant infantile spasms - Evaluate the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms
Part B: - Evaluate the efficacy of radiprodil in abolishing clinical spasms and achieving the resolution of hypsarrhythmia (or other disordered interictal electroencephalogram (EEG) patterns consistent with the diagnosis) in subjects with drug-resistant infantile spasms - Evaluate the safety and tolerability of radiprodil in subjects with drug-resistant infantile spasms
Part C: - Investigate the safety and tolerability of radiprodil over repeated treatment cycles - Investigate the efficacy of radiprodil in infants who have responded to 2 treatment cycles in Part A but experienced a relapse within 3 days of treatment cessation |
|
E.2.2 | Secondary objectives of the trial |
Part A: - Evaluate resolution of hypsarrhythmia (or other disordered interictal EEG patterns consistent with the diagnosis) in subjects with drug-resistant infantile spasms - Evaluate long-term developmental outcomes after treatment with radiprodil in subjects with drug-resistant infantile spasms
Part B: - Evaluate the pharmacokinetics of radiprodil in subjects with drug-resistant infantile spasms - Evaluate long-term development outcomes after treatment with radiprodil in subjects with drug-resistant infantile spasms
Part C: - Evaluate long-term developmental outcomes after repeated treatment cycles of radiprodil
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Parts A and B: - Subject is male or female between 2 and 14 months of age - The diagnosis of infantile spasms (IS) - Subject has drug-resistant IS
Part C: - Subject participated in EP0078 Part A and received 2 radiprodil treatment cycles - Subject experienced a relapse of spasms during the down taper or within 5 half-lives (3 days) discontinuation of radiprodil treatment in Cycle 2 of Part A - Electroencephalogram (EEG) on baseline Part C is compatible with the diagnosis of infantile spasms |
|
E.4 | Principal exclusion criteria |
Parts A and B: - More than 6 months have passed since the diagnosis of IS. - Subject has hematocrit greater than 60 - Subject has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject’s ability to participate in this study - Subject has a history or current condition predisposing to respiratory dysfunction - Current treatment with felbamate - Ketogenic diet - Clinically significant lab abnormalities - Clinically significant abnormality on ECG that, in the opinion of the Investigator, increases the safety risks of participating in the study - Subject has a lethal or potentially lethal condition other than IS, with a significant risk of death before 18 months of age - Body weight is below 4 kg - Known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias - Current treatment with perampanel - Current treatment with cannabinoids
Part C: - Subject experienced any acute tolerability issues in either treatment cycle in Part A which the investigator and the sponsor medical monitor consider a risk for further participation - Subject met any withdrawal criteria in Part A - Subject has experienced any adverse effects or developed any new medical conditions since enrollment in Part A which the investigator considers could significantly increase the safety risks of participating in Part C |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Part A: - Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil
Part B: - Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil
All Parts: - Incidence of Adverse Events (AEs) during the study |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Part A: - Day 14, counting from the first day of radiprodil at maintenance dose - Pharmacokinetic samples will be collected using Mitra microsampling technique at baseline (this sample may be taken at any time during Day -14 to Day -1 prior to dosing) and 3hr, 4hr, 5hr and 12hr after the first dose on Day 1 of radiprodil low dose, Day 1 of radiprodil mid dose and Day 1 of radiprodil high dose, Additionally, blood samples will be taken at same timepoints after 1st dose on Day 2 of radiprodil low dose"
Part B: - Day 14, counting from the first day of radiprodil at maintenance dose
All Parts: From Baseline (Day -1) to the end of the Post-treatment Period (28 days post last dosing) |
|
E.5.2 | Secondary end point(s) |
Part A: - Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil
Part B: - Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil
Part A and Part B: - Time to cessation of spasms - Percentage of responders with clinical relapse - Time to clinical relapse from the day of spasm cessation - Percentage of electro-clinical responders with electro-clinical relapse - Time to electro-clinical relapse from the day of spasm cessation - Percentage of subjects with extended clinical response - Percentage of subjects with extended electro-clinical response - Estimates of exposure generated from a population-Pharmacokinetic modelling
Part C: - Percentage of subjects with extended clinical response to each additional treatment cycle on Day 14 of treatment with the maintenance dose of radiprodil - Number of treatment cycles per subject - Percentage of subjects with electro-clinical response to each additional treatment cycle on Day 14 of treatment with the maintenance dose of radiprodil - Time to clinical relapse from the first day of no witnessed spasms for each treatment cycle. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part A and B: - Day 14, counting from Day 14 of treatment with the maintenance dose of radiprodil - During the first 14 days of treatment with radiprodil - 12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil - From day of spasms cessation up to 42 months of age - 28 days, counting from Day 14 (incl) of maintenance dose
Part B: - Pharmacokinetic samples will be collected on Day 1 of radiprodil low dose, mid dose and high dose. Additionally, blood samples will be taken after 1st dose on Day 2 of radiprodil low dose
Part C: - 28 days, counting from Day 14 (incl.) of maintenance dose - During Part C (Day -1 to Day 28 of the Maintenance Period) - Day 14, counting from the first day of maintenance dose - From day of no witnessed spasms up to 42 months of age
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
France |
Germany |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last Subject Last Visit (LSLV) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |